All shares to be sold by the company. Proceeds will fund clinical and research activities.
AGIO is one of the few recent IPOs to buck the sector's recent downtrend. After a strong debut on July 24 when prices closed up almost 74% from the $18 offer, prices eased to a low of $15.77 on November 18. The stock has been in an uptrend since then, albeit with substantial volatility. Today's $40.85 close represents a tidy 159% gain from November's low.
The stock sports a respectable Relative Strength rating of 84 (best=99) compared to the biotech sector's (IBB +2.3%) 59.